Literature DB >> 15488776

Quality of life in keratoconus.

Steven M Kymes1, Jeffrey J Walline, Karla Zadnik, Mae O Gordon.   

Abstract

PURPOSE: Keratoconus is a chronic, noninflammatory disease of the cornea with onset in early adulthood. As these years are important to financial and social health, keratoconus may have more severe impact on quality of life than would be expected given its clinical severity. We examined the vision-related quality of life of patients in the Collaborative Longitudinal Evaluation of Keratoconus (CLEK) Study.
DESIGN: Cross-sectional study.
METHODS: The National Eye Institute-Visual Function Questionnaire (NEI-VFQ) was administered to 1166 CLEK Study patients at their first annual follow-up examination. Associations between clinical and demographic factors and NEI-VFQ scale scores were evaluated.
RESULTS: Binocular entrance visual acuity worse than 20/40 was associated with lower quality of life scores on all scales except General Health and Ocular Pain. A steep keratometric reading (average of both eyes) >52 diopters (D) was associated with lower scores on the Mental Health, Role Difficulty, Driving, Dependency, and Ocular Pain scales. Scores for CLEK patients on all scales were between patients with category 3 and category 4 age-related macular degeneration (AMD) except General Health, which was better than AMD patients, and Ocular Pain, which was worse than AMD patients.
CONCLUSIONS: Keratoconus is a disease of relatively low prevalence that rarely results in blindness, but because it affects young adults, the magnitude of its public health impact is disproportionate to its prevalence and clinical severity.

Entities:  

Mesh:

Year:  2004        PMID: 15488776     DOI: 10.1016/j.ajo.2004.04.031

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  52 in total

1.  Use of patient-reported outcomes in medical product development: a report from the 2009 NEI/FDA Clinical Trial Endpoints Symposium.

Authors:  Rohit Varma; Elaine A Richman; Frederick L Ferris; Neil M Bressler
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-12       Impact factor: 4.799

2.  [Enzymatic evidence of the depth dependence of stiffening on riboflavin/UVA treated corneas].

Authors:  T Schilde; M Kohlhaas; E Spoerl; L E Pillunat
Journal:  Ophthalmologe       Date:  2008-02       Impact factor: 1.059

3.  Collaborative Longitudinal Evaluation of Keratoconus (CLEK) Study: methods and findings to date.

Authors:  H Wagner; J T Barr; K Zadnik
Journal:  Cont Lens Anterior Eye       Date:  2007-05-03       Impact factor: 3.077

4.  A Large-Scale Computational Analysis of Corneal Structural Response and Ectasia Risk in Myopic Laser Refractive Surgery.

Authors:  William Joseph Dupps; Ibrahim Seven
Journal:  Trans Am Ophthalmol Soc       Date:  2016-08

5.  Trends in Corneal Transplantation in Keratoconus.

Authors:  Daniel Sarezky; Stephen E Orlin; Wei Pan; Brian L VanderBeek
Journal:  Cornea       Date:  2017-02       Impact factor: 2.651

Review 6.  Corneal collagen cross-linking: a review.

Authors:  David P S O'Brart
Journal:  J Optom       Date:  2014-03-20

7.  Discriminant value of custom ocular response analyzer waveform derivatives in keratoconus.

Authors:  Katie M Hallahan; Abhijit Sinha Roy; Renato Ambrosio; Marcella Salomao; William J Dupps
Journal:  Ophthalmology       Date:  2013-11-26       Impact factor: 12.079

8.  Intrastromal corneal ring implants for corneal thinning disorders: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2009-04-01

9.  Collagen cross-linking using riboflavin and ultraviolet-a for corneal thinning disorders: an evidence-based analysis.

Authors:  G Pron; L Ieraci; K Kaulback
Journal:  Ont Health Technol Assess Ser       Date:  2011-11-01

10.  The quality of life impact of peripheral versus central vision loss with a focus on glaucoma versus age-related macular degeneration.

Authors:  Keith Evans; Simon K Law; John Walt; Patricia Buchholz; Jan Hansen
Journal:  Clin Ophthalmol       Date:  2009-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.